Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
GHENT, Belgium, May 20, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major...
-
REGULATED INFORMATION GHENT, Belgium, May 14, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced its non-audited business update, summarising Ablynx's financial position for...
-
GHENT, Belgium, May 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] announces that it will be presenting at the 2014 UBS Global Life Sciences Conference, which is taking place from 19...
-
GHENT, Belgium, May 6, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has obtained positive results from two additional Phase I studies, utilising its wholly-owned...
-
REGULATED INFORMATION GHENT, Belgium, April 30, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX], today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding...
-
GHENT, Belgium, April 23, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that...
-
GHENT, Belgium, April 23, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has started dose administration in healthy volunteers in a Phase I clinical trial as part of...
-
GHENT, Belgium, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced its consolidated results for 2013, which have been prepared in accordance with IFRS as adopted by the...
-
GHENT, Belgium, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2013 on Thursday 27 February 2014 at 7.00 am CET. The Ablynx management...
-
Utilising the Nanobody® technology to generate multi-specific drugs GHENT, Belgium, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX], today announced that the company has...